Pharmacy Retail
Search documents
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Walgreens Boots Alliance, Inc. and Certain Officers – WBA
GlobeNewswire News Room· 2025-03-26 12:00
Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged violations of federal securities laws during the Class Period from April 2, 2020, to January 16, 2025, seeking damages for affected investors [1] Company Overview - Walgreens operates as a healthcare, pharmacy, and retail company in the U.S., U.K., Germany, and internationally, with three reportable segments: U.S. Retail Pharmacy, International, and U.S. Healthcare [4] - The U.S. Retail Pharmacy segment includes retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, with a significant portion of sales derived from prescription drugs reimbursed by third-party payors [4] Legal and Regulatory Context - Walgreens must comply with various federal statutes, including the Controlled Substances Act (CSA) and the False Claims Act (FCA), which govern the dispensation of controlled substances and reimbursement claims [5][6] - The opioid crisis in the U.S. has led to increased scrutiny of Walgreens' practices, with the company previously settling multiple legal claims related to its role in the opioid epidemic [6][7] Allegations and Lawsuit Details - The complaint alleges that Walgreens made materially false and misleading statements regarding its business operations and compliance with federal laws, leading to unsustainable revenues from unlawful conduct [9] - The Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging the company dispensed millions of unlawful prescriptions and sought reimbursement from federal health care programs [10] - Following the DOJ's announcement, Walgreens' stock price fell by 12.06%, indicating a significant market reaction to the allegations [10]
Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
Globenewswire· 2025-03-12 12:30
Core Insights - The company has reported a significant increase in gift card sales due to a smart savings program for GLP-1 diabetes and weight loss medications, driven by consumer demand for cost-saving healthcare solutions [1][3] - CardCash.com, the company's secondary gift card exchange platform, saw a remarkable 916% week-over-week increase in the face value of gift cards sold at major pharmacy retailers [2] - The company has increased its inventory levels to meet the growing demand for pharmacy gift cards, ensuring competitive discount rates while supporting healthcare accessibility [3][4] Sales and Inventory Growth - The surge in sales is attributed to innovative savings opportunities for high-cost prescription medications like Ozempic and Zepbound, alongside increased demand for seasonal health products [2][4] - CVS inventory levels grew by 120% year-over-year, while Walgreens inventory experienced a 736% increase [8] Strategic Focus - The company emphasizes its pharmacy gift card program to address the need for affordable access to newer treatment options, supporting broader healthcare accessibility [4] - The CEO highlighted that the growth in sales validates the company's strategic expansion into the healthcare sector [3]
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 31, 2025 in Walgreens Lawsuit - WBA
Prnewswire· 2025-03-12 09:45
Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Walgreens made false statements and concealed ongoing violations of federal law regarding prescription medication dispensation and reimbursement [2]. - It is alleged that Walgreens' conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful practices, rendering public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].